BR112017013286A2 - composto de isoxazolina, e, uso de um composto de isoxazolina. - Google Patents

composto de isoxazolina, e, uso de um composto de isoxazolina.

Info

Publication number
BR112017013286A2
BR112017013286A2 BR112017013286-9A BR112017013286A BR112017013286A2 BR 112017013286 A2 BR112017013286 A2 BR 112017013286A2 BR 112017013286 A BR112017013286 A BR 112017013286A BR 112017013286 A2 BR112017013286 A2 BR 112017013286A2
Authority
BR
Brazil
Prior art keywords
isoxazoline compound
isoxazoline
compound
administering
formula
Prior art date
Application number
BR112017013286-9A
Other languages
English (en)
Inventor
Williams Heike
Regina Heckeroth Anja
Tänzler Janina
Joël Alain Frenais Régis
Original Assignee
Intervet International B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International B.V. filed Critical Intervet International B.V.
Publication of BR112017013286A2 publication Critical patent/BR112017013286A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

a presente invenção refere-se a métodos para tratar demodicose por administração de um composto de isoxazolina de fórmula (i) .
BR112017013286-9A 2014-12-22 2015-12-21 composto de isoxazolina, e, uso de um composto de isoxazolina. BR112017013286A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14199562 2014-12-22
EP14199562.1 2014-12-22
PCT/EP2015/080744 WO2016102437A1 (en) 2014-12-22 2015-12-21 Use of isoxazoline compounds for treating demodicosis

Publications (1)

Publication Number Publication Date
BR112017013286A2 true BR112017013286A2 (pt) 2018-03-06

Family

ID=52146273

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017013286-9A BR112017013286A2 (pt) 2014-12-22 2015-12-21 composto de isoxazolina, e, uso de um composto de isoxazolina.

Country Status (9)

Country Link
US (3) US20170348286A1 (pt)
EP (2) EP3236960A1 (pt)
JP (1) JP6706262B2 (pt)
CN (2) CN106999475B (pt)
AU (3) AU2015371175B2 (pt)
BR (1) BR112017013286A2 (pt)
CA (1) CA2971296A1 (pt)
RU (1) RU2709198C2 (pt)
WO (1) WO2016102437A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2971296A1 (en) 2014-12-22 2016-06-30 Intervet International B.V. Use of isoxazoline compounds for treating demodicosis
WO2018039508A1 (en) * 2016-08-25 2018-03-01 Merial, Inc. Method for reducing unwanted effects in parasiticidal treatments
CN107501199A (zh) * 2017-08-16 2017-12-22 南京农业大学 氟雷拉纳单体化合物的提取和纯化方法
IL307992A (en) * 2017-12-15 2023-12-01 Tarsus Pharmaceuticals Inc Parasitic formulations containing isoxazoline and methods for treating blepharitis
US11880349B2 (en) 2019-04-30 2024-01-23 Salesforce, Inc. System or method to query or search a metadata driven distributed ledger or blockchain

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2067863C1 (ru) * 1994-05-25 1996-10-20 Казанский государственный технологический университет Акарицидный состав для лечения чесотки домашних животных
CA2558848C (en) 2004-03-05 2013-11-19 Nissan Chemical Industries, Ltd. Isoxazoline-substituted benzamide compound and pesticide
DE102004053964A1 (de) * 2004-11-09 2006-05-11 Bayer Healthcare Ag Mittel gegen Demodikose
TWI412322B (zh) 2005-12-30 2013-10-21 Du Pont 控制無脊椎害蟲之異唑啉
TWI430995B (zh) 2007-06-26 2014-03-21 Du Pont 萘異唑啉無脊椎有害動物控制劑
KR101714291B1 (ko) 2007-06-27 2017-03-08 이 아이 듀폰 디 네모아 앤드 캄파니 동물 해충 방제 방법
TWI556741B (zh) * 2007-08-17 2016-11-11 英特威特國際股份有限公司 異唑啉組成物及其作為抗寄生蟲藥上的應用
TWI411395B (zh) 2007-12-24 2013-10-11 Syngenta Participations Ag 殺蟲化合物
US8377942B2 (en) 2008-12-18 2013-02-19 Novartis Ag Isoxazolines derivatives and their use as pesticide
CN102256971B (zh) * 2008-12-19 2014-09-17 诺华股份有限公司 作为杀虫剂的异噁唑啉衍生物及其用途
CN105616406B (zh) 2010-12-27 2019-12-13 英特维特国际股份有限公司 外用局部异噁唑啉制剂
CN108125951A (zh) 2010-12-27 2018-06-08 英特维特国际股份有限公司 包含三缩四乙二醇的外用局部异噁唑啉制剂
HUE029810T2 (en) * 2011-03-10 2017-03-28 Zoetis Services Llc Spirocyclic isoxazole derivatives as antiparasitic agents
EP3788874A1 (en) * 2011-09-12 2021-03-10 Boehringer Ingelheim Animal Health USA Inc. Parasiticidal compositions comprising an isoxazoline active agent, method and uses thereof
RU2660346C1 (ru) 2012-02-06 2018-07-05 Мериал, Инк. Паразитицидные пероральные ветеринарные композиции, включающие системно действующие активные агенты, способы и применение этих композиций и способов
NZ631100A (en) 2012-04-04 2016-06-24 Intervet Int Bv Soft chewable pharmaceutical products
WO2014090918A1 (en) * 2012-12-13 2014-06-19 Novartis Ag Process for the enantiomeric enrichment of diaryloxazoline derivatives
JP6581586B2 (ja) * 2013-12-20 2019-09-25 インターベット インターナショナル ベー． フェー． イソオキサゾリン組成物および動物における寄生虫侵襲の予防または処置におけるその使用
CA2971296A1 (en) 2014-12-22 2016-06-30 Intervet International B.V. Use of isoxazoline compounds for treating demodicosis

Also Published As

Publication number Publication date
EP3236960A1 (en) 2017-11-01
AU2021203686A1 (en) 2021-07-01
EP4008329A1 (en) 2022-06-08
RU2017126029A (ru) 2019-01-24
CA2971296A1 (en) 2016-06-30
CN106999475A (zh) 2017-08-01
AU2023219972A1 (en) 2023-09-14
US20170348286A1 (en) 2017-12-07
RU2709198C2 (ru) 2019-12-17
CN114681453A (zh) 2022-07-01
JP6706262B2 (ja) 2020-06-03
US10799483B2 (en) 2020-10-13
AU2015371175A1 (en) 2017-06-15
US20180318265A1 (en) 2018-11-08
AU2015371175B2 (en) 2021-03-04
RU2017126029A3 (pt) 2019-06-20
CN106999475B (zh) 2022-10-25
JP2017538767A (ja) 2017-12-28
US20200405692A1 (en) 2020-12-31
WO2016102437A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
BR112018073384A2 (pt) polinucleotídeos moduladores
EA201692219A1 (ru) Способы получения противовирусных соединений
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
CR20170100A (es) Indazoles sustituidos con bencilo como inhibidores bub1
BR112016019871A2 (pt) anticorpos anti-cd38 para o tratamento de leucemia linfoblástica aguda
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
EA201692338A1 (ru) Соединения 5-хлор-дифторметоксифенил-пиразолопиримидина, представляющие собой ингибиторы янус-киназы
EA201790266A1 (ru) Индолы для применения при инфекции, вызванной вирусом гриппа
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
BR112019010131A2 (pt) entrega transdérmica de agentes grandes
CL2016001349A1 (es) Uso de derivados de bencimidazol-prolina
BR112017008176A2 (pt) método de preparação do carbonato de ácido glicérico.
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
MX2017002214A (es) Proceso para la preparacion de 5-fluoro-1h-pirazoles partiendo de hexafluoropropeno.
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
BR112017009471A2 (pt) síntese de copanlisib e seu sal de di-hidrocloreto.
BR112017002662A2 (pt) processo para preparar furfural e/ou derivados de furfural.
GT201600066A (es) Composiciones y métodos para inhibir la expresión del gen alas1
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
EA201691412A1 (ru) Гидроксиформамидные производные и их применение
BR112015019924A2 (pt) métodos e composições para tratar leucemia
CL2017000151A1 (es) Derivados de piridona
MX2016015543A (es) Proceso para la preparacion de 5-fluoro-1h-pirazoles a partir de hexafluoropropeno.
EA201790687A1 (ru) Хинолинкарбоксамиды для применения в лечении множественной миеломы
DOP2016000211A (es) Pirazinas moduladoras de gpr6

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B154 Notification of filing of divisional application [chapter 15.50 patent gazette]

Free format text: O PEDIDO FOI DIVIDIDO NO BR122022022387-7 PROTOCOLO 870220101799 EM 03/11/2022 19:17.

B12B Appeal against refusal [chapter 12.2 patent gazette]